Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• One of the following histologically confirmed diagnoses:
• * Stage I non-small cell lung cancer (NSCLC)
• * No small cell component
• * Stage I-II squamous cell cancer of the head and neck
• * No WHO type II or III nasopharyngeal cancer
• * No sinonasal undifferentiated carcinoma
• No evidence of disease
• Must have undergone surgery or radiotherapy with curative intent within the past 4-24 weeks
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-1
• Life expectancy
• Not specified
• Hematopoietic
• Platelet count at least 50,000/mm\^3
• Hepatic
• Bilirubin normal
• AST/ALT no greater than 2 times upper limit of normal
• Renal
• Creatinine no greater than 2.0 mg/dL
• Cardiovascular
• No uncontrolled hypertension
• No severe congestive heart failure
• Pulmonary
• No history of asthma caused by cyclooxygenase-2 (COX-2) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, or sulfonamides
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after study participation
• No other prior malignancy (including skin cancer and in situ malignancies)
• No diagnosis of peptic ulcer disease or gastritis/esophagitis within the past 60 days
• No prior hypersensitivity reaction to COX-2 inhibitors, NSAIDs, salicylates, or sulfonamides
• No other concurrent medical condition that would preclude study compliance
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• Not specified
• Endocrine therapy
• No cumulative oral or IV corticosteroid use totalling more than 2 weeks within the past 3 months
• No concurrent oral steroids for more than 2 consecutive weeks
• Concurrent inhaled steroids allowed
• Radiotherapy
• See Disease Characteristics
• No prior definitive radiotherapy for stage I NSCLC
• Surgery
• See Disease Characteristics
• Prior pneumonectomy or lobectomy with mediastinal lymph node sampling or dissection for stage I NSCLC allowed
• No prior segmentectomies or wedge resections for stage I NSCLC
• Other
• More than 60 days since prior treatment for peptic ulcer disease or gastritis/esophagitis
• No prior NSAID use within the past 30 days at a frequency of 3 or more times a week for more than 2 weeks
• No concurrent NSAIDs (including low-dose aspirin)
• No other concurrent COX-2 inhibitors
• No concurrent fluconazole
• No concurrent lithium